FOLH1 and neoplasm: Due to the long half-life, a pre-therapeutic estimation of the resulting absorbed doses of PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 might be possible by [89Zr]Zr-PSMA-617 PET/CT since delayed imaging allows individual determination of the biological half-life of each tumor lesion and of the organs-at-risk.